Research News

Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

(May 4, 2020) On April 29th, the Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) as a first-line maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of BRCA…

Read on

SGO 2020 Highlights

(April 17, 2020) The Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer brings together women’s healthcare professionals from across the globe to discuss the latest findings in gynecologic oncology…

Read on

COVID-19 and Oncology Clinical Trials: An Update

(April 15) The novel coronavirus, COVID-19, has become nearly all consuming. It’s impossible to turn on the news, browse social media, or walk outside without being reminded of the new, albeit temporary, state of the world…

Read on

Working for the Next Generation | Meet a Scientist

There are many adjectives one can use to describe ovarian cancer: relentless, cruel, a monster. But Dr. Sunila Pradeep also finds it ironic. “Women spend a lot of time and energy for the next generation…

Read on

Study Uncovers Barriers to Clinical Trial Participation

(April 9, 2020) Why do some gynecologic cancer patients participate in clinical trials, while others do not? Clinical trials are fundamental to the discovery of new and better therapies in the fight against ovarian cancer…

Read on

Update to Benefits of Breastfeeding Against Ovarian Cancer

(April 7, 2020) In a study published last week in the oncology Journal of the American Medical Association, breastfeeding was found to be a factor for reduced risk of developing invasive ovarian cancer…

Read on

A Letter from our President | Update on our Mission and Programs During the COVID-19 Pandemic

Friends, I hope this finds you well, or as well as can be expected during this challenging time. My wish for all of you is that you are feeling safe, and surrounded by caring community…

Read on

Statins Present New Directions for Ovarian Cancer Research

(3/17/2020) Research out of the University of Bristol looked at genes and how they inhibit an enzyme involved in regulating the body’s cholesterol. This enzyme is the target of statin drugs, which are prescribed to lower cholesterol levels…

Read on

PARP Inhibitors in Ovarian Cancer Treatment: What’s Next?

(February 13, 2020) PARP inhibitors have shown to be a promising treatment option for a subset of ovarian cancer patients…

Read on

Conversation on Link Between Talcum Powder and Ovarian Cancer Continues with New Prospective Study

(January 15, 2020) A new study in the Journal of the American Medical Association (JAMA) found no statistically significant association between self-reported use of powder in the genital area and subsequent risk of developing ovarian cancer…

Read on

OCRA Awards $6.6 Million in Ovarian Cancer Research Grants for 2020

(January 13, 2020) Thanks to your support, 22 top scientists at 19 eminent medical centers across the world will delve into important topics across the ovarian cancer landscape…

Read on

OCRA-Funded Research Advances Immunotherapy

(December 23, 2019) OCRA-funded scientist Dr. Sarah Gitto is making strides toward better harnessing the immune system to fight ovarian cancer. As reported recently in Gynecologic Oncology, Dr…

Read on